688238.SHG OBiO Technology (Shanghai) Corp. Ltd. A
- Market cap
- CNY 4.13B
- P/E
- -
- P/B
- 3.02x
- ROE
- -15.5%
- Dividend yield
- 0.20%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688238.SHG undervalued?
Graham numberThe Graham number of OBiO Technology (Shanghai) Corp. Ltd. A cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OBiO Technology (Shanghai) Corp. Ltd. A fundamental analysis
No fundamental analysis for OBiO Technology (Shanghai) Corp. Ltd. A yet.
OBiO Technology (Shanghai) Corp. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OBiO Technology (Shanghai) Corp. Ltd. A
Shanghai Obio Technology (Group) Corp., Ltd., a biotechnology company, engages in the provision of technical services for the field of regenerative medicine and anti-aging in China and internationally. The company offers customized plasmid design and viral vector packaging services; AAV serotypes and tissue-specific promoters to support scientific research; and research grade, NHP Grade, cGMP grade vector manufacturing process, for basic research, translational research and …
Full company profileOBiO Technology (Shanghai) Corp. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
OBiO Technology (Shanghai) Corp. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 62.9M | 143M | 255M | 291M | 205M | 248M | 268M | 244M |
| Gross Profit | 24.5M | 83.0M | 131M | 129M | -13.1M | -93.8M | -38.9M | -19.2M |
| Operating Income | -40.1M | 18.8M | 50.1M | 15.0M | -156M | -261M | -206M | -190M |
| EBITDA | -34.3M | 99.3M | 83.7M | 69.5M | -114M | -220M | -127M | -192M |
| Net Income | -36.5M | 94.4M | 54.3M | 39.3M | -128M | -322M | -235M | -203M |
| EPS | -0.39 | 0.18 | 0.11 | 0.06 | -0.20 | -0.50 | -0.36 | -0.31 |
| Balance Sheet | ||||||||
| Total Assets | 205M | 1.01B | 1.26B | 2.50B | 2.60B | 2.28B | 2.09B | 2.00B |
| Total Liabilities | 111M | 165M | 346M | 325M | 545M | 545M | 684M | 692M |
| Shareholders' Equity | 84.9M | 849M | 918M | 2.17B | 2.06B | 1.74B | 1.41B | 1.31B |
| Cash & Short-term Investments | 48.0M | 455M | 619M | 1.24B | 657M | 439M | 293M | 178M |
| Cash Flow | ||||||||
| Operating Cash Flow | -23.2M | 62.3M | 109M | 21.4M | -90.1M | -61.1M | -103M | - |
| Capital Expenditure | 35.8M | 95.9M | 262M | 484M | 547M | 167M | 126M | 109M |
| Free Cash Flow | -59.0M | -33.6M | -153M | -463M | -637M | -229M | -229M | -275M |
| Ratios | ||||||||
| ROE | -43.0% | 11.1% | 5.9% | 1.8% | -6.2% | -18.5% | -16.7% | -15.5% |
| ROA | -17.8% | 9.3% | 4.3% | 1.6% | -4.9% | -14.1% | -11.2% | -10.1% |
| Net Profit Margin | -58.1% | 66.1% | 21.3% | 13.5% | -62.5% | -129.7% | -87.8% | -83.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
OBiO Technology (Shanghai) Corp. Ltd. A dividends
- Dividend yield
- 0.20%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 8.35M | 0.01 | - |
| 2024 | CNY 6.37M | 0.01 | - |
| 2023 | CNY 5.02M | 0.01 | - |
| 2022 | CNY 5.10M | 0.01 | 13.0% |
| 2021 | - | - | - |
| 2020 | CNY 2.53M | 0.00 | 2.7% |
| 2019 | CNY 2.55M | 0.03 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on May 30, 2023.
Who owns OBiO Technology (Shanghai) Corp. Ltd. A
- Insiders 28.22%
- Institutions 9.60%
- Public & others 62.19%
- Shares outstanding 649M
- Free float 458M
OBiO Technology (Shanghai) Corp. Ltd. A company profile
- Company name
- OBiO Technology (Shanghai) Corp. Ltd. A
- Ticker
- 688238.SHG
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 715
- Fiscal year end
- December
- Address
- International Medical Park, Shanghai, China, 201321
- Phone
- 86 21 5858 5887
- Website
- obiosh.com
About OBiO Technology (Shanghai) Corp. Ltd. A
Shanghai Obio Technology (Group) Corp., Ltd., a biotechnology company, engages in the provision of technical services for the field of regenerative medicine and anti-aging in China and internationally. The company offers customized plasmid design and viral vector packaging services; AAV serotypes and tissue-specific promoters to support scientific research; and research grade, NHP Grade, cGMP grade vector manufacturing process, for basic research, translational research and clinical trials. It also provides CDMO services encompassing process development, analytical methods, IND-enabling chemistry, manufacturing, and controls; and clinical and commercial manufacturing for viral vector, oncolytic virus, and cell therapy products, as well as engages in the production and sales of biological raw materials, biological agents, reagents, and other products. The company was formerly known as Obio Technology (Shanghai) Corp., Ltd. and change its name to Shanghai Obio Technology (Group) Corp., Ltd. in March 2026. The company was founded in 2013 and is headquartered in Shanghai, China.
OBiO Technology (Shanghai) Corp. Ltd. A management
10- Mr. Oudong PanFounder & Chairman of the Board · born 1968
- Mr. Junyi PanGM & Director · born 1994
- Ms. Luyuan XuDeputy GM, Accounting Supervisor & Board Secretary · born 1970
- Ms. Shan YinDeputy GM & Director · born 1982
- Ms. Qingmei XiaDeputy General Manager · born 1979
- Ms. Qinbin WuDeputy General Manager · born 1972
- Ms. Jiali YangDeputy Director of R&D · born 1986
- Mr. Houliang WeiVice President of Process Development · born 1988
- Mr. Haizi ChengTechnical R&D Director · born 1984
- Ms. Suli LiuCDMO Project Manager · born 1984